| News & Announcements | Pharmaceutical Treatments of COVID-19 for Independence Medicare Advantage Members (Updated May 4, 2021) | | | | | | 5/4/2021 | | | Pharmaceutical Treatments of COVID-19 for Independence Medicare Advantage Members (Updated May 4, 2021) | |
| News & Announcements | Telehealth Services for Medicare Advantage Members (updated May 7, 2021) | | | | | | 5/7/2021 | | | Telehealth Services for Medicare Advantage Members (updated May 7, 2021) | |
| News & Announcements | Telehealth Services for Medicare Advantage Members (Updated March 19, 2021) | | | | | | 5/7/2021 | | | Telehealth Services for Medicare Advantage Members (Updated March 19, 2021) | |
| News & Announcements | Telehealth Services for Medicare Advantage Members (Updated March 19, 2021) | | | | | | 5/7/2021 | | | Telehealth Services for Medicare Advantage Members (Updated March 19, 2021) | |
| News & Announcements | Telehealth Services for Medicare Advantage Members (Updated March 19, 2021) | | | | | | 5/8/2021 | | | Telehealth Services for Medicare Advantage Members (Updated March 19, 2021) | |
| News & Announcements | Telehealth Services for Medicare Advantage Members (updated May 13, 2021) | | | | | | 5/13/2021 | | | Telehealth Services for Medicare Advantage Members (updated May 13, 2021) | |
| News & Announcements | Ground Ambulance Transport Services (Emergency and Nonemergency) for Medicare Advantage Members (Updated May 20, 2021) | | | | | | 5/20/2021 | | | Ground Ambulance Transport Services (Emergency and Nonemergency) for Medicare Advantage Members (Updated May 20, 2021) | |
| Notifications | Inebilizumab-cdon (Uplizna) | MA08.126b | 5/11/2021 1:00 PM | 8/9/2021 | | | 5/11/2021 | Medical Necessity Criteria;General Description, Guidelines, or Informational Update | | Inebilizumab-cdon (Uplizna) | |
| New Policies | Melphalan flufenamide (Pepaxto®) | MA08.135 | | 5/10/2021 | | | 5/10/2021 | This is a New Policy. | | Melphalan flufenamide (Pepaxto®) | |
| New Policies | Filgrastim (Neupogen ®) and related biosimilars, and Tbo-filgrastim (Granix ®) | MA08.130 | 12/31/2020 10:00 AM | 4/1/2021 | | | 5/13/2021 | This is a New Policy. | 5/13/2021 | Filgrastim (Neupogen ®) and related biosimilars, and Tbo-filgrastim (Granix ®) | |
| New Policies | Teprotumumab (Tepezza™) | MA08.115 | 4/23/2021 10:00 AM | 5/24/2021 | | | 5/24/2021 | This is a New Policy. | | Teprotumumab (Tepezza™) | |
| New Policies | evinacumab-dgnb (Evkeeza) | MA08.133 | | 5/24/2021 | | | 5/24/2021 | This is a New Policy. | | evinacumab-dgnb (Evkeeza) | |
| Updated Policies | Botulinum Toxin Agents | MA08.017f | | 5/3/2021 | | | 5/3/2021 | Medical Necessity Criteria;Medical Coding | | Botulinum Toxin Agents | |
| Updated Policies | Contrast Agents Used in Conjunction with Echocardiography | MA09.004c | 4/2/2021 2:00 PM | 5/3/2021 | | | 5/3/2021 | General Description, Guidelines, or Informational Update | | Contrast Agents Used in Conjunction with Echocardiography | |
| Updated Policies | Denosumab (Prolia®, Xgeva®), Romosozumab-aqqg (Evenity®) | MA08.052i | | 5/10/2021 | | | 5/10/2021 | Medical Necessity Criteria | | Denosumab (Prolia®, Xgeva®), Romosozumab-aqqg (Evenity®) | |
| Updated Policies | Fam-trastuzumab deruxtecan-nxki (Enhertu®) | MA08.114b | | 5/24/2021 | | | 5/24/2021 | Medical Necessity Criteria;Medical Coding | | Fam-trastuzumab deruxtecan-nxki (Enhertu®) | |
| Updated Policies | Lurbinectedin (Zepzelca) | MA08.125b | | 5/24/2021 | | | 5/24/2021 | Medical Necessity Criteria | | Lurbinectedin (Zepzelca) | |
| Updated Policies | Isatuximab-irfc (Sarclisa®) | MA08.117b | | 5/24/2021 | | | 5/24/2021 | Medical Necessity Criteria;General Description, Guidelines, or Informational Update | | Isatuximab-irfc (Sarclisa®) | |
| Updated Policies | Fecal Microbiota Transplantation (FMT) | MA07.006b | | 5/31/2021 | | | 5/28/2021 | Medical Necessity Criteria;General Description, Guidelines, or Informational Update | | Fecal Microbiota Transplantation (FMT) | |
| Reissue Policies | belantamab mafodotin-blmf (Blenrep) | MA08.119b | | 4/1/2021 | 5/5/2021 | | 5/5/2021 | | | belantamab mafodotin-blmf (Blenrep) | |
| Reissue Policies | crizanlizumab-tmca (Adakveo®) | MA08.109a | | 10/1/2020 | 5/5/2021 | | 5/5/2021 | | | crizanlizumab-tmca (Adakveo®) | |
| Reissue Policies | Acupuncture | MA12.004b | | 1/1/2021 | 5/7/2021 | | 5/7/2021 | | | Acupuncture | |
| Reissue Policies | Screening for Vertebral Fracture with Dual-Energy X-ray Absorptiometry (DEXA/DXA) | MA09.013a | | 2/18/2016 | 5/5/2021 | | 5/7/2021 | | | Screening for Vertebral Fracture with Dual-Energy X-ray Absorptiometry (DEXA/DXA) | |
| Reissue Policies | Positron Emission Mammography (PEM) | MA09.015 | | 1/1/2015 | 5/5/2021 | | 5/7/2021 | | | Positron Emission Mammography (PEM) | |
| Reissue Policies | Moxetumomab pasudotox-tdfk (Lumoxiti™) | MA08.103b | | 10/1/2019 | 5/5/2021 | | 5/7/2021 | | | Moxetumomab pasudotox-tdfk (Lumoxiti™) | |
| Reissue Policies | Cerliponase alfa (Brineura®) | MA08.089c | | 6/3/2019 | 5/5/2021 | | 5/10/2021 | | 5/10/2021 | Cerliponase alfa (Brineura®) | |
| Reissue Policies | Emapalumab-lzsg (Gamifant®) | MA08.104b | | 10/1/2019 | 5/5/2021 | | 5/10/2021 | | 5/10/2021 | Emapalumab-lzsg (Gamifant®) | |
| Reissue Policies | Compression Garments | MA05.045a | | 5/6/2016 | 5/19/2021 | | 5/21/2021 | | | Compression Garments | |
| Reissue Policies | Negative Pressure Wound Therapy (NPWT) Systems | MA05.008b | | 8/17/2020 | 5/19/2021 | | 5/21/2021 | | | Negative Pressure Wound Therapy (NPWT) Systems | |
| Reissue Policies | Composite Tissue Allotransplantation of the Hand(s) and Face | MA11.112 | | 5/21/2017 | 5/19/2021 | | 5/21/2021 | | | Composite Tissue Allotransplantation of the Hand(s) and Face | 5/21/2021 |
| Reissue Policies | Percutaneous Intradiscal Annuloplasty (IDET/PIRFT) | MA11.025 | | 1/1/2015 | 5/19/2021 | | 5/21/2021 | | | Percutaneous Intradiscal Annuloplasty (IDET/PIRFT) | |
| Reissue Policies | Computer-Assisted Musculoskeletal Surgical Navigational Orthopedic Procedure | MA11.088c | | 12/29/2020 | 5/19/2021 | | 5/21/2021 | | | Computer-Assisted Musculoskeletal Surgical Navigational Orthopedic Procedure | |
| Reissue Policies | Percutaneous Image-Guided Lumbar Decompression (PILD) for Spinal Stenosis | MA11.097d | | 12/16/2019 | 5/19/2021 | | 5/21/2021 | | | Percutaneous Image-Guided Lumbar Decompression (PILD) for Spinal Stenosis | |
| Reissue Policies | Non-Surgical Spinal Decompression Therapy | MA11.021a | | 3/28/2016 | 5/19/2021 | | 5/21/2021 | | | Non-Surgical Spinal Decompression Therapy | |
| Reissue Policies | Speech and Non-Speech Generating Devices | MA05.003d | | 7/6/2020 | 5/19/2021 | | 5/21/2021 | | | Speech and Non-Speech Generating Devices | |
| Reissue Policies | Pulse Oximeters in the Home Setting | MA05.042a | | 5/7/2018 | 5/19/2021 | | 5/21/2021 | | | Pulse Oximeters in the Home Setting | |
| Reissue Policies | Cryosurgical Ablation of the Prostate Gland | MA11.022a | | 4/7/2015 | 5/19/2021 | | 5/24/2021 | | | Cryosurgical Ablation of the Prostate Gland | |
| Reissue Policies | Mogamulizumab-kpkc (Poteligeo®) | MA08.102c | | 1/18/2021 | 5/19/2021 | | 5/24/2021 | | | Mogamulizumab-kpkc (Poteligeo®) | |
| Reissue Policies | Luspatercept–aamt (Reblozyl®) | MA08.110b | | 7/1/2020 | 5/19/2021 | | 5/24/2021 | | | Luspatercept–aamt (Reblozyl®) | |
| Reissue Policies | Dofetilide (Tikosyn®) Use in the Inpatient Setting | MA08.021b | | 9/22/2019 | 5/19/2021 | | 5/24/2021 | | | Dofetilide (Tikosyn®) Use in the Inpatient Setting | |
| Reissue Policies | Edaravone (Radicava®) | MA08.092a | | 12/28/2018 | 5/19/2021 | | 5/24/2021 | | | Edaravone (Radicava®) | |
| Reissue Policies | Ocrelizumab (Ocrevus®) | MA08.088c | | 9/17/2019 | 5/19/2021 | | 5/24/2021 | | | Ocrelizumab (Ocrevus®) | |
| Reissue Policies | Sebelipase alfa (Kanuma®) | MA08.078d | | 6/18/2020 | 5/19/2021 | | 5/24/2021 | | | Sebelipase alfa (Kanuma®) | |
| Reissue Policies | Tagraxofusp-erzs (Elzonris®) | MA08.105c | | 5/23/2020 | 5/19/2021 | | 5/24/2021 | | | Tagraxofusp-erzs (Elzonris®) | |
| Reissue Policies | Eculizumab (Soliris®) and Related Biosimilars, Ravulizumab-cwvz (Ultomiris™) | MA08.044f | | 4/20/2020 | 5/19/2021 | | 5/24/2021 | | | Eculizumab (Soliris®) and Related Biosimilars, Ravulizumab-cwvz (Ultomiris™) | |
| Reissue Policies | Composite Tissue Allotransplantation of the Hand(s) and Face | MA11.112 | | 5/21/2017 | 5/19/2021 | | 5/24/2021 | | | Composite Tissue Allotransplantation of the Hand(s) and Face | |